| Date | Title | Description |
| 24.10.2024 | Innovate Cambridge launches strategy to accelerate innovation through increased startup investment | Cambridge, UK has unveiled a plan to supercharge the impact of the Greater Cambridge area by doubling the rate at which it builds unicorns, doubling the venture capital investment the city’s startups receive, and creating twice as many scie... |
| 25.05.2024 | ETF Partners Raises €285M for Sustainability Ventures | ETF Partners, Europe's original sustainability venture capital firm, has successfully raised €285 million in an oversubscribed round for its fourth fund. Founded in 2006, ETF Partners focuses on investing in fast-growing innovative companie... |
| 24.05.2024 | Bicycle Therapeutics scores $555M investment for disease prevention | Cambridge medtech Bicycle Therapeutics has raised $555M in equity financing via a private placement.
Bicycle Therapeutics draws on Sir Gregory Winter's Nobel-winning research to trial use of ‘bicycle’ molecules in cancer treatment by penetr... |
| 24.05.2024 | €2.5B for NanoIC pilot line, ETF Partners raises €285M, and 10 Italian startups to watch | This week our research tracked more than 65 tech funding deals worth over €4.3 billion, and 15 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the m... |
| 23.05.2024 | Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing | - Financing includes participation from new and existing investors
- Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027
- Supports ongoing ... |
| 19.09.2022 | Bicycle announces publication of article highlighting preclinical data from BT8009 program in molecular cancer therapeutics | Bicycle Therapeutics announces publication of article highlighting preclinical data from BT8009 program in molecular cancer therapeutics
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated cla... |
| 12.07.2022 | Bicycle Therapeutics announces further expansion of Genentech Immuno-Oncology collaboration | Bicycle Therapeutics announces further expansion of Genentech Immuno-Oncology collaboration
Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement
Bicycle Therapeutics plc (NASDAQ: BCYC), ... |
| 04.11.2021 | Bicycle Therapeutics reports third quarter 2021 financial results and provides corporate update | Bicycle Therapeutics reports third quarter 2021 financial results and provides corporate update
Announced interim BT5528 Phase I clinical trial results and preliminary results from ongoing BT8009 Phase I clinical trial
First Patient Dosed i... |
| 13.10.2021 | Bicycle Therapeutics : Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares | Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the pricing of an underwritten publi... |
| 12.10.2021 | Bicycle Therapeutics : Announces Proposed $125,000,000 Public Offering of American Depositary Shares | Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has commenced an underwritte... |
| 15.07.2021 | Bicycle Therapeutics enters exclusive $45 million licence and collaboration agreement with Ionis | Bicycle Therapeutics enters exclusive $45 million licence and collaboration agreement with Ionis
15-07-2021
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on ... |
| 13.07.2021 | Bicycle Therapeutics enters exclusive license and collaboration agreement with Ionis | Bicycle Therapeutics enters exclusive license and collaboration agreement with Ionis to develop targeted oligonucleotide therapeutics
Bicycle to receive a total of $45 million upfront from Ionis and is eligible for development, regulatory a... |
| 27.01.2021 | A year in review: Business update January 2021 | Cambridge has always been at the forefront of innovation. As the leading venture capital investor in Cambridge, CIC plays a central role in commercialising this innovation for the benefit of society. In the last year, CIC’s existing portfol... |
| 06.11.2020 | Bicycle Therapeutics reports third quarter 2020 financial results and provides corporate update | Bicycle Therapeutics reports third quarter 2020 financial results and provides corporate update
06-11-2020
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on it... |
| 01.10.2020 | Bicycle announces gross proceeds of $50M from its at-the-market offering programme | Bicycle Therapeutics announces gross proceeds of $50.0 Million from its at-the-market offering Programme and enters into debt financing from Hercules Capital
ATM offering program initiated during Q3’20 fully utilized; $15.0 million drawn on... |
| 10.09.2020 | Bicycle announces first patient dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 | Bicycle Therapeutics announces first patient dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in patients with advanced solid tumors
BT8009 is the third program designed to explore the potential of Bicycles® as next-generation t... |
| 02.09.2020 | Bicycle announces first patient dosed in Phase IIa trial | Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718
Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional c... |
| 22.06.2020 | Annual results for the year ended 31 March 2020 | Expansion to 30 portfolio companies and 46% increase in net asset value, reinforcing CIC’s position as the most active series A investor in the Cambridge ecosystem
Cambridge Innovation Capital plc (CIC), the venture capital investor enablin... |
| 01.05.2020 | How the UK life sciences industry is rising to the challenge of Covid-19 by Kate Bingham | Crisis is the mother of invention and Covid-19 is no exception. But amid all the gloom are signs of a nascent revolution in how we create and develop new drugs, vaccines and diagnostics. The UK life sciences industry is rising to the challe... |
| 07.04.2020 | Bicycle Therapeutics Announces Pipeline Progress Update | - Phase I dose escalation completed for BT1718—RP2D established and preliminary signs of anti-tumor activity observed, including one partial response |
| 08.11.2019 | Cambridge companies recognised at industry leading OBN Awards 2019 event | Cambridge companies recognised at industry leading OBN Awards 2019 event
08-11-2019
Cambridge Network members Bicycle Therapeutics and Endomag have been honoured at the 2019 OBN Awards, which celebrate the best of UK life sciences.
OBN (UK)... |
| 22.05.2019 | Bicycle Therapeutics announce pricing of Initial Public Offering | Bicycle Therapeutics announce pricing of Initial Public Offering
Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, ... |
| 07.05.2019 | Bicycle Therapeutics enters neuroscience arena | Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced a collaboration with the Dementia Discovery Fund (DDF) to use Bicycl... |
| 24.04.2019 | Bicycle Therapeutics and Oxurion announce full enrollment in Phase I trial | Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, and Oxurion today announced full enrollment of Oxurion’s Phase I trial designed to e... |
| 12.02.2019 | Bicycle Therapeutics awarded SBRI contract to address antimicrobial resistance | Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced it has been awarded a contract from the Department of Health and Soc... |
| 24.05.2018 | Bicycle Therapeutics expands strategic partnership with AstraZeneca | New programmes added in Respiratory and Cardio-Metabolic Diseases
Bicycle Therapeutics has announced that it is expanding its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.
The ori... |
| 13.02.2018 | Bicycle Therapeutics and CRUK announce initiation of first clinical study of a bicyclic peptide | Cancer Research UK and Bicycle Therapeutics have announced that the first patient has been dosed in their Phase I/IIa trial evaluating BT1718 in patients with advanced solid tumors. BT1718 is a first-in-class Bicycle Toxin Conjugate being d... |
| 08.01.2018 | Bicycle Therapeutics secures Innovate UK grant to develop the next generation of antibiotics | Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced that it has been awarded a grant from Innovate UK, the UK’s innovation age... |
| 08.01.2018 | Bicycle Therapeutics secures Innovate UK grant to develop the next generation of antibiotics | Bicycle Therapeutics secures Innovate UK grant to develop the next generation of antibiotics
08-01-2018
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®... |
| 04.01.2018 | Bicycle Therapeutics awarded Innovate UK grant to develop novel antibiotics | Bicycle Therapeutics has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.
The Innovate UK funding will be used to develop Bicycles with uniqu... |
| 04.01.2018 | Bicycle Therapeutics Secures an Innovate UK Grant | Bicycle Therapeutics, a Cambridge, UK-based biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, has been awarded a grant from Innovate UK, the UK’s innovation agency.
The ... |
| 14.12.2017 | Awards for Cambridge Medical Robotics and Bicycle Therapeutics | CIC portfolio companies continue to win accolades, with Cambridge Medical Robotics recently included in FierceMedTech's 2017 Fierce 15 as well as listed as one of the Sunday Times/Virgin Media’s top 10 Business Disruptors.
At the same time ... |
| 06.09.2017 | Bioverativ and Bicycle Therapeutics enter into strategic research collaboration | Bioverativ Inc, a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for haemophilia and other rare blood disorders, and Bicycle Therapeutics Ltd have announced a research collab... |
| 02.06.2017 | Temasek-backed Vertex Ventures leads $51m Series B in UK’s Bicycle Therapeutics | Premium
UK-based biotechnology venture Bicycle Therapeutics has closed a £40 million ($51.4 million) Series B financing round led by Vertex Ventures HC.
Continue reading this story with a subscription to DealStreetAsia.
Subscribe
Already a ... |
| 01.06.2017 | CIC invests in £40 million fundraise for Bicycle Therapeutics | Cambridge Innovation Capital has invested as part of a £40 million Series B financing round for Bicycle Therapeutics.
Bicycle Therapeutics is pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) produc... |
| 01.06.2017 | Bicycle Therapeutics, co-founded by blockbuster drug developer, raises £40m | Bicycle Therapeutics, co-founded by blockbuster drug developer, raises £40m
01-06-2017
The top blockbuster drug for 2016 was based on the techniques developed by Professor Sir Gregory Winter. Now his latest Cambridge company, Bicycle Therap... |
| 01.06.2017 | Bicycle Therapeutics Closes £40 Million ($52 Million) Series B | CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the succ... |
| 01.06.2017 | Term Sheet — Thursday, June 1 | EXITS AND CONFLICTS
NYC Tech: Awhile back I had promised to provide updated deal data comparing exits for startups from NYC, LA and Boston. We can’t compare deal value of M&A exits since so many of the prices are not confirmed. For exam... |
| 01.06.2017 | Bicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline | - |
| 01.06.2017 | Bicycle Therapeutics Closes £40M in Series B Financing | Bicycle Therapeutics, a Cambridge, England, UK-based biotechnology company advancing a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, completed a £40m Series B funding.
The round was led by ... |
| 01.06.2017 | Bicycle Therapeutics picks up speed with $52M Series B | It’s a very real risk as excitement builds around its novel peptide-based technology. Over the last seven years, the company has fine-tuned and industrialized the platform, explained CEO Kevin Lee, and many doors are now opening up.
“In tha... |
| 01.12.2016 | Bicycle Therapeutics announces partnership with AstraZeneca to develop bicyclic peptides | Bicycle Therapeutics announces partnership with AstraZeneca to develop bicyclic peptides
01-12-2016
Bicycle Therapeutics, a Babraham-based biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptid... |
| 14.10.2014 | Bicycle Therapeutics Raises $32M in Funding | Bicycle Therapeutics, a Cambridge, UK-based biotech firm focused on developing bicyclic peptides, raised $32m in funding.
Backers included previous investors Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences and Astellas Ventur... |
| 14.10.2014 | Pharma VCs cluster behind a brainchild of UK biotech pioneer Sir Greg Winter | While Atlas Venture was busy putting together a syndicate for Raze in Cambridge, MA, the venture group was also engaged in hatching a $32 million round across the Atlantic in the scientific hotbed of Cambridge, UK. Atlas partnered with SV L... |
| 01.02.2013 | Investment Record for EPFL Spin-offs | |
| 10.12.2012 | Bicycle Therapeutics announces £3.75 million financing for drug discovery | Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of £3.75 million to invest in selection of drug... |
| 10.12.2012 | Bicycle Therapeutics Raises £3.75M in Funding | Bicycle Therapeutics, a Cambridge, U.K.-based biotechnology company, has raised £3.75m (approximately $6m) in new funding.
Backers include existing investors Atlas Venture, Novartis Venture Fund, SR One and SV Life Sciences and new investor... |
| 10.12.2012 | Bicycle Therapeutics announces £3.75 million financing for drug discovery | Bicycle Therapeutics announces £3.75 million financing for drug discovery
10-12-2012
Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it ha... |
| 10.12.2012 | Bicycle Therapeutics Rides 3.75M Pounds |
CAMBRIDGE, ENGLAND, Next generation biotherapeutics company, co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of 3.75 million pounds.
>> Click here for... |
| 23.05.2010 | Bicycle Therapeutics Receives Additional Seed Funding | Bicycle Therapeutics Ltd, a Babraham Research Campus, Cambridge, UK-based biotechnology company developing a novel technology platform for the identification and optimisation of chemically constrained cyclic peptides with high target specif... |
| 06.10.2009 | UK, Bicycle Therapeutics Secures Seed Funding | Bicycle Therapeutics Ltd, a new biotechnology company developing a novel technology platform for the creation of a new generation of biotherapeutics, has secured seed funding from Atlas Venture and Novartis Venture Fund.
Bicycle Therapeutic... |
| - | Bicycle Therapeutics picks up speed with $52M Series B | You can’t not include puns in a story about a startup called Bicycle Therapeutics. The best you can do is pick ones that are relevant. So without further ado:
Cambridge, U.K.-based Bicycle Therapeutics is trying not to pedal too fast.
It’s ... |
